keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28633806/il-17-for-therapy
#1
REVIEW
Florian C Kurschus, Sonja Moos
The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis. Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also recently approved by the FDA for plaque psoriasis. Using mice overexpressing IL-17A in a tissue of choice, we showed that the ectopic expression of this cytokine in keratinocytes resulted in a spontaneous and very strong form of psoriasis-like dermatitis...
June 15, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28625883/tcr-cd3-cd4-cd8-effector-t-cells-in-psoriasis
#2
D Brandt, M Sergon, S Abraham, K Mäbert, C M Hedrich
The autoimmune/inflammatory disorder psoriasis is characterized by keratinocyte proliferation and immune cell infiltration of the skin. TCR(+)CD3(+)CD4(-)CD8(-) "double negative" (DN) T cells can derive from CD8(+) T cells through the down-regulation of CD8. The inhibitory molecule programmed death (PD-)1 is expressed on activated T cells and plays a role in the maintenance of peripheral tolerance. A subset of DN T cells, characterized by the expression of PD-1, has recently been demonstrated to be self-reactive...
June 15, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28624255/-psoriatic-patients-analysis-of-patients-dissatisfied-with-their-management
#3
E Mahé, F Maccari, A Beauchet, N Quiles-Tsimaratos, N Beneton, J Parier, H Barthelemy, C Goujon-Henry, G Chaby, D Thomas-Beaulieu, G Géner, L Wagner, V Pallure, S Devaux, A Vermersch-Langlin, P Pfister, J Jégou, C Livideanu, M-L Sigal
BACKGROUND: The French are frequently regarded as grouchy. In a recent study, we observed a high proportion of patients initially consulting for psoriasis because they were dissatisfied with their previous therapy. We analyzed the characteristics of these patients. PATIENTS AND METHODS: This was a cross-sectional multicenter study in 40 centers belonging to the ResoPso (psoriasis treatment network) multicenter study group, with consecutive inclusions over a period of 11months in 2014...
June 14, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28624119/skin-infiltrating-interleukin-22-producing-t-cells-differentiate-pediatric-psoriasis-from-adult-psoriasis
#4
Kelly M Cordoro, Maria Hitraya-Low, Keyon Taravati, Priscila Munoz Sandoval, Esther Kim, Jeffrey Sugarman, Mariela L Pauli, Wilson Liao, Michael D Rosenblum
BACKGROUND: Evidence from adult psoriasis studies implicates an imbalance between regulatory and effector T cells, particularly TH-17-producing T cells, in the pathogenesis of psoriasis. Little is known about the immunopathology of psoriasis in children. OBJECTIVE: We sought to functionally characterize the inflammatory cell profiles of psoriatic plaques from pediatric patients and compare them with healthy, age-matched controls and adult psoriasis patients. METHODS: Skin samples from pediatric psoriasis patients and healthy controls were analyzed by multiparameter flow cytometry to determine the dominant immune cell subsets present and cytokines produced...
June 14, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28621164/effect-of-psoriasis-activity-and-topical-treatment-on-plasma-epidermal-growth-factor-egf-and-its-soluble-receptor-segfr
#5
M Szterling-Jaworowska, A Baran, H Myśliwiec, I Flisiak
BACKGROUND: Pathogenesis of psoriasis involves epidermal growth factor (EGF) which participates in keratinocyte proliferation, angiogenesis and cell differentiation through binding to soluble epidermal growth factor receptor (sEGFR). It is synthesised by, among others, keratinocytes, especially within psoriatic skin. OBJECTIVE: To evaluate EGF and sEGFR plasma concentrations during topical psoriatic treatment. METHODS: Blood samples were collected from 51 patients with plaque psoriasis...
June 16, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28620097/interleukin-17-family-cytokines-signaling-mechanisms-biological-activities-and-therapeutic-implications
#6
Leticia Monin, Sarah L Gaffen
The cytokines of the interleukin 17 (IL-17) family play a central role in the control of infections, especially extracellular fungi. Conversely, if unrestrained, these inflammatory cytokines contribute to the pathology of numerous autoimmune and chronic inflammatory conditions. Recent advances have led to the approval of IL-17A-blocking biologics for the treatment of moderate to severe plaque psoriasis, but much remains to be understood about the biological functions, regulation, and signaling pathways downstream of these factors...
June 15, 2017: Cold Spring Harbor Perspectives in Biology
https://www.readbyqxmd.com/read/28611623/visual-loss-induced-by-adalimumab-used-for-plaque-psoriasis
#7
Norman Saffra, Konstantin Astafurov
A 61-year-old Caucasian male with severe plaque psoriasis without joint involvement was initiated on adalimumab therapy. Shortly thereafter he presented to the emergency room with acute loss of vision in the right eye. A comprehensive systemic workup was instituted which included magnetic resonance imaging (MRI) with and without gadolinium of the brain and orbits. MRI revealed findings that were consistent with CNS demyelination and retrobulbar optic neuritis. Immediate cessation of adalimumab was instituted without any other systemic therapy...
January 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28611622/psoriatic-alopecia-in-a-patient-with-systemic-lupus-erythematosus
#8
Wimolsiri Iamsumang, Tueboon Sriphojanart, Poonkiat Suchonwanit
Psoriasis is a chronic, recurrent, and relatively common inflammatory dermatologic condition, which demonstrates various clinical manifestations including hair loss. It was once believed that alopecia was not a presentation of scalp psoriasis, but it is now widely accepted that psoriatic alopecia exists. Although the majority of patients get hair regrowth, it can potentially lead to permanent hair loss. Herein, we report a case of 26-year-old female patient with systemic lupus erythematosus who presented with scalp hair loss and nonpruritic scaly plaques on the scalp...
January 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28608740/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-plaque-psoriasis-in-japan
#9
Shinichi Imafuku, Ataru Nakano, Hidetoshi Dakeshita, Junlong Li, Keith A Betts, Annie Guerin
BACKGROUND: Biologics have been shown to improve the outcomes of patients with psoriasis but their cost is an issue. OBJECTIVE: Determine the number needed to treat (NNT) to achieve a 75%/90% reduction in the Psoriasis Area and Severity Index (PASI-75/90) and evaluate the incremental cost per PASI-75/90 responder (CPR) relative to placebo in Japan. METHODS: A network meta-analysis was conducted to estimate the relative probabilities of achieving PASI-75/90 and NNTs...
June 13, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28604055/deciphering-the-mechanism-of-action-of-wrightia-tinctoria-for-psoriasis-based-on-systems-pharmacology-approach
#10
Sudharsana Sundarrajan, Sajitha Lulu, Mohanapriya Arumugam
OBJECTIVE: Psoriasis is a chronic immune-mediated disorder of the skin. The disease manifests itself with red or silvery scaly plaques distributing over the lower back, scalp, and extensor aspects of limbs. Several medications are available for the treatment of psoriasis; however, high rates of remission and side-effects still persist as a major concern. Siddha, one of the traditional systems of Indian medicine offers cure to many dermatological conditions, including psoriasis. The oil prepared from the leaves of Wrightia tinctoria is prescribed by many healers for the treatment of psoriasis...
June 12, 2017: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
https://www.readbyqxmd.com/read/28602039/secukinumab-demonstrates-greater-sustained-improvements-in-daily-activities-and-personal-relationships-than-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-52-week-results-from-the-clear-study
#11
A Blauvelt, K Reich, S Mehlis, F Vanaclocha, H Sofen, W Abramovits, Y Zhao, I Gilloteau, E Davenport, N Williams, A Guana, S Tyring
BACKGROUND: Psoriasis can greatly impact patients' lives by influencing clothing worn as well as by impairing sexual functioning. Secukinumab, a human monoclonal antibody selectively neutralizing interleukin-17A, has demonstrated good efficacy and safety in the treatment of moderate-to-severe psoriasis and psoriatic arthritis with a rapid onset of action and sustained response. OBJECTIVE: This analysis using the CLEAR study, a phase 3b double-blind study comparing the efficacy and safety of secukinumab versus ustekinumab in adults with moderate-to-severe plaque psoriasis, evaluated the treatment effects on patient's daily activities and personal relationships...
June 11, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28602032/comparative-evaluation-of-efficacy-and-safety-of-calcipotriol-versus-tacalcitol-ointment-both-in-combination-with-nbuvb-phototherapy-in-the-treatment-of-stable-plaque-psoriasis
#12
Ishita Dua, Kamal Aggarwal, V K Jain
BACKGROUND: Vitamin D analogues and NBUVB phototherapy are both well-established modalities of treatment in psoriasis. The objective of this open label, intra individual, left right study was to compare two different Vitamin D analogues, calcipotriol and tacalcitol, in combination with NBUVB phototherapy in chronic stable plaque psoriasis. METHODS: Thirty patients with stable plaque psoriasis were enrolled for a 12 week clinical trial. The target lesion on left side was treated topically with tacalcitol ointment once daily, while that on the right side was treated with calcipotriol ointment twice daily...
June 11, 2017: Photodermatology, Photoimmunology & Photomedicine
https://www.readbyqxmd.com/read/28600818/extension-of-ustekinumab-maintenance-dosing-interval-in-moderate-to-severe-psoriasis-results-of-a-phase-3b-randomized-double-blinded-active-controlled-multicenter-study-pstellar
#13
A Blauvelt, L K Ferris, P S Yamauchi, A Qureshi, C L Leonardi, K Farahi, S Fakharzadeh, M-C Hsu, S Li, M Chevrier, K Smith, K Goyal, Y Chen, E J Muñoz-Elías, K Callis Duffin
BACKGROUND: Phase 3 studies showed some patients maintained response for ≥6 months post-ustekinumab discontinuation. OBJECTIVES: To assess clinical responses with extended ustekinumab maintenance dosing intervals. METHODS: Adults with moderate-to-severe plaque psoriasis received ustekinumab (45mg/90mg for weight ≤100 kg/>100 kg) at Week0, Week4, Week16 during open-label treatment. Patients achieving a Week 28 Physician's Global Assessment score of cleared/minimal (PGA=0/1) were randomized 1:4 to Group1 (approved every-12-weeks [q12wk] maintenance) or Group2 (q12-24wk response-based dosing determined by time-to-loss-of-PGA=0/1)...
June 10, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28596043/tildrakizumab-versus-placebo-or-etanercept-for-chronic-plaque-psoriasis-resurface-1-and-resurface-2-results-from-two-randomised-controlled-phase-3-trials
#14
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li, Kenneth Liu, Carmen La Rosa, Stuart Green, Alexa B Kimball
BACKGROUND: Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis. Previous research suggested clinical improvement with inhibition of interleukin 23 p19. We did two phase 3 trials to investigate whether tildrakizumab is superior to placebo and etanercept in the treatment of chronic plaque psoriasis. METHODS: We did two three-part, parallel group, double-blind, randomised controlled studies, reSURFACE 1 (at 118 sites in Australia, Canada, Japan, the UK, and the USA) and reSURFACE 2 (at 132 sites in Europe, Israel, and the USA)...
June 5, 2017: Lancet
https://www.readbyqxmd.com/read/28589404/erratum-to-secukinumab-is-efficacious-and-safe-in-hispanic-patients-with-moderate-to-severe-plaque-psoriasis-pooled-analysis-of-four-phase-3-trials
#15
Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado-García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana
No abstract text is available yet for this article.
June 6, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28585891/in%C3%A2-vitro-psoriasis-models-with-focus-on-reconstructed-skin-models-as-promising-tools-in-psoriasis-research
#16
Eline Desmet, Anesh Ramadhas, Jo Lambert, Mireille Van Gele
Psoriasis is a complex chronic immune-mediated inflammatory cutaneous disease associated with the development of inflammatory plaques on the skin. Studies proved that the disease results from a deregulated interplay between skin keratinocytes, immune cells and the environment leading to a persisting inflammatory process modulated by pro-inflammatory cytokines and activation of T cells. However, a major hindrance to study the pathogenesis of psoriasis more in depth and subsequent development of novel therapies is the lack of suitable pre-clinical models mimicking the complex phenotype of this skin disorder...
June 2017: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28585707/early-relapse-of-psoriasis-after-stopping-brodalumab-a-retrospective-cohort-study-in-77-patients
#17
M Masson Regnault, M-P Konstantinou, A Khemis, Y Poulin, M Bourcier, F Amelot, C Bulaï Livideanu, C Paul
BACKGROUND: Biological agents targeting IL-17 are very effective for clearing moderate to severe psoriasis. There is limited information regarding the frequency and pattern of psoriasis relapse upon treatment cessation. OBJECTIVE: To investigate the pattern of psoriasis recurrence in patients who were treated with brodalumab following Amgen's decision to stop the clinical program in June 2015. MATERIALS AND METHODS: Between June 2015 and March 2016, we constructed a retrospective multicenter cohort study including patients who were treated with brodalumab in Amgen's protocols after the abrupt interruption of the drug development program...
June 6, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28585342/european-consensus-statement-on-phenotypes-of-pustular-psoriasis
#18
REVIEW
Alexander A Navarini, A David Burden, Francesca Capon, Ulrich Mrowietz, Luis Puig, Sulev Köks, Külli Kingo, Catherine Smith, Jonathan N Barker
Pustular psoriasis (PP) is a group of inflammatory skin conditions characterized by infiltration of neutrophil granulocytes in the epidermis to such an extent that clinically visible sterile pustules develop. Because of clinical co-incidence, PP is currently grouped with psoriasis vulgaris (PV). However, PP and PV are phenotypically different, respond differently to treatments, and seem to be distinct on the genetic level. In contrast to PV, the phenotypes of PP are not well defined. Descriptions of each form of PP are discordant among standard dermatology textbooks [1-5], encumbering the collection of phenotypically well-matched groups of patients as well as clinical trials...
June 6, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28585093/serum-fatty-acid-profile-in-psoriasis-and-its-comorbidity
#19
Hanna Myśliwiec, Anna Baran, Ewa Harasim-Symbor, Piotr Myśliwiec, Anna Justyna Milewska, Adrian Chabowski, Iwona Flisiak
Psoriasis is a chronic inflammatory skin disease that is accompanied by metabolic disturbances and cardio-metabolic disorders. Fatty acids (FAs) might be a link between psoriasis and its comorbidity. The aim of the study was to evaluate serum concentrations of FAs and to investigate their association with the disease activity, markers of inflammation and possible involvement in psoriatic comorbidity: obesity, type 2 diabetes and hypertension. We measured 14 total serum fatty acids content and composition by gas-liquid chromatography and flame-ionization detector after direct in situ transesterification in 85 patients with exacerbated plaque psoriasis and in 32 healthy controls...
June 5, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28580646/secukinumab-is-superior-to-fumaric-acid-esters-in-treating-subjects-with-moderate-to-severe-plaque-psoriasis-who-are-na%C3%A3-ve-to-systemic-treatments-results-from-the-randomized-controlled-prime-trial
#20
M Sticherling, U Mrowietz, M Augustin, D Thaçi, N Melzer, C Hentschke, J Kneidl, C Sieder, K Reich
BACKGROUND: Secukinumab is a fully human antibody that neutralizes IL-17A and has significant efficacy and a favorable safety profile in moderate to severe plaque psoriasis and psoriatic arthritis. METHODS: In this 24-week, randomized, open-label, multicenter study with blinded assessment, subjects with moderate to severe plaque psoriasis, naïve to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral fumaric acid esters (FAE)...
June 5, 2017: British Journal of Dermatology
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"